Janux Therapeutics, Inc. (JANX)
$18.10-$0.75 (-3.99%) Today
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 4,059 | $57K |
| Grant or award | 14 | 147,000 | |
| Option exercise | 2 | 14,000 | |
| Bona-fide gift | 1 | 123,840 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
27 Form 4 filings on record, the earliest from Oct 18, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Alan Campbell - Officer | Gift | Common Stock | 123,840 | $0.00 | - | |
| David Alan Campbell - Officer | Option exercise | Common Stock | 7,000 | $4.21 | $29K | |
| David Alan Campbell - Officer | Option exercise | Stock Option (right to buy) | 7,000 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Stock Option (Right to Buy) | 15,500 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Common Stock | 5,500 | $0.00 | - | |
 Jake Simson | Grant or award | Common Stock | 5,500 | $0.00 | - | |
| Jake Simson | Grant or award | Stock Option (right to buy) | 15,500 | $0.00 | - | |
| Winston Kung | Grant or award | Stock Option (right to buy) | 15,500 | $0.00 | - | |
| Winston Kung | Grant or award | Common Stock | 5,500 | $0.00 | - | |
| Natasha Hernday | Grant or award | Common Stock | 5,500 | $0.00 | - | |
| Natasha Hernday | Grant or award | Stock Option (right to buy) | 15,500 | $0.00 | - | |
| Eric Dobmeier | Grant or award | Common Stock | 5,500 | $0.00 | - | |
| Eric Dobmeier | Grant or award | Stock Option (right to buy) | 15,500 | $0.00 | - | |
| Vickie L. Capps | Grant or award | Common Stock | 5,500 | $0.00 | - | |
| Vickie L. Capps | Grant or award | Stock Option (right to buy) | 15,500 | $0.00 | - | |
| Ronald W. Barrett | Grant or award | Common Stock | 5,500 | $0.00 | - | |
| Ronald W. Barrett | Grant or award | Stock Option (right to buy) | 15,500 | $0.00 | - | |
| Janeen Noel Doyle - Officer | Open-market sale | Common Stock | 4,059 | $14.03 | $57K | |
| Maria Dobek - Officer | Open-market sale | Common Stock | 2,038 | $14.17 | $29K | |
| William Go - Officer | Grant or award | Common Stock | 44,000 | $0.00 | - | |
| William Go - Officer | Grant or award | Stock option (right to buy) | 154,000 | $0.00 | - | |
| Andrew Hollman Meyer - Officer | Option exercise | Common Stock | 3,333 | $10.59 | $35K | |
| Andrew Hollman Meyer - Officer | Open-market sale | Common Stock | 2,700 | $32.85 | $89K | |
| Andrew Hollman Meyer - Officer | Open-market sale | Common Stock | 633 | $33.52 | $21K | |
| Andrew Hollman Meyer - Officer | Option exercise | Stock Option (right to buy) | 3,333 | $0.00 | - | |
| Andrew Hollman Meyer - Officer | Option exercise | Common Stock | 3,333 | $10.59 | $35K | |
| Andrew Hollman Meyer - Officer | Open-market sale | Common Stock | 3,333 | $30.00 | $100K | |
| Andrew Hollman Meyer - Officer | Option exercise | Stock Option (right to buy) | 3,333 | $0.00 | - | |
| Andrew Hollman Meyer - Officer | Option exercise | Common Stock | 9,999 | $4.21 | $42K | |
| Andrew Hollman Meyer - Officer | Option exercise | Common Stock | 6,666 | $10.59 | $71K | |
| Andrew Hollman Meyer - Officer | Open-market sale | Common Stock | 16,665 | $30.06 | $501K | |
| Andrew Hollman Meyer - Officer | Option exercise | Stock Option (right to buy) | 9,999 | $0.00 | - | |
| Andrew Hollman Meyer - Officer | Option exercise | Stock Option (right to buy) | 6,666 | $0.00 | - | |
| Eric Dobmeier | Grant or award | Common Stock | 3,750 | $0.00 | - | |
| Eric Dobmeier | Grant or award | Stock Option (right to buy) | 11,667 | $0.00 | - | |
| Vickie L. Capps | Grant or award | Common Stock | 3,750 | $0.00 | - | |
| Vickie L. Capps | Grant or award | Stock Option (right to buy) | 11,667 | $0.00 | - | |
| David Alan Campbell - Officer | Open-market sale | Common Stock | 25,000 | $56.19 | $1.40M | |
| Andrew Hollman Meyer - Officer | Option exercise | Common Stock | 9,880 | $20.24 | $200K | |
| Andrew Hollman Meyer - Officer | Option exercise | Common Stock | 1 | $14.02 | $14 | |
| Andrew Hollman Meyer - Officer | Option exercise | Stock Option (right to buy) | 9,880 | $0.00 | - | |
| Andrew Hollman Meyer - Officer | Option exercise | Stock Option (right to buy) | 1 | $0.00 | - | |
| David Alan Campbell - Officer | Open-market sale | Common Stock | 15,000 | $67.00 | $1.00M | |
| David Alan Campbell - Officer | Open-market sale | Common Stock | 18,281 | $51.43 | $940K | |
| David Alan Campbell - Officer | Open-market sale | Common Stock | 6,719 | $52.04 | $350K | |
| Vickie L. Capps | Other | Common Stock | 2,305 | $0.00 | - | |
| Sheila Gujrathi | Other | Common Stock | 4,611 | $0.00 | - | |
| David Alan Campbell - Officer | Open-market sale | Common Stock | 13,897 | $53.22 | $740K | |
| David Alan Campbell - Officer | Open-market sale | Common Stock | 11,103 | $53.94 | $599K | |
| Jay Lichter | Option exercise | Common Stock | 1,868 | $17.00 | $32K | |
| Jay Lichter | Option exercise | Common Stock | 778 | $10.73 | $8K | |
| Jay Lichter | Option exercise | Common Stock | 778 | $13.22 | $10K | |
| Jay Lichter | Option exercise | Common Stock | 391 | $39.80 | $16K | |
| Jay Lichter | Open-market sale | Common Stock | 3,815 | $46.68 | $178K | |
| Jay Lichter | Option exercise | Stock Option (right to buy) | 1,868 | $0.00 | - | |
| Jay Lichter | Option exercise | Stock Option (right to buy) | 778 | $0.00 | - | |
| Jay Lichter | Option exercise | Stock Option (right to buy) | 778 | $0.00 | - | |
| Jay Lichter | Option exercise | Stock Option (right to buy) | 391 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 1,200,000 | $44.75 | $53.70M | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 60,179 | $49.69 | $2.99M | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 11,657 | $49.69 | $579K | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 61,445 | $49.69 | $3.05M | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 29,474 | $50.61 | $1.49M | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 5,710 | $50.61 | $289K | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 30,094 | $50.61 | $1.52M | |
| Avalon Ventures XI, L.P. | Option exercise | Common Stock | 4,968 | $17.00 | $84K | |
| Avalon Ventures XI, L.P. | Option exercise | Common Stock | 2,070 | $10.73 | $22K | |
| Avalon Ventures XI, L.P. | Option exercise | Common Stock | 2,070 | $13.22 | $27K | |
| Avalon Ventures XI, L.P. | Option exercise | Common Stock | 1,407 | $39.80 | $56K | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 10,957 | $50.80 | $557K | |
| Avalon Ventures XI, L.P. | Option exercise | Common Stock | 836 | $17.00 | $14K | |
| Avalon Ventures XI, L.P. | Option exercise | Common Stock | 348 | $10.73 | $4K | |
| Avalon Ventures XI, L.P. | Option exercise | Common Stock | 348 | $13.22 | $5K | |
| Avalon Ventures XI, L.P. | Option exercise | Common Stock | 237 | $39.80 | $9K | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 1,843 | $50.02 | $92K | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 102,732 | $50.30 | $5.17M | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 19,900 | $50.30 | $1.00M | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 104,892 | $50.30 | $5.28M | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 15,462 | $51.18 | $791K | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 2,995 | $51.18 | $153K | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 15,788 | $51.18 | $808K | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 541,824 | $44.75 | $24.25M | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 104,957 | $44.75 | $4.70M | |
| Avalon Ventures XI, L.P. | Open-market sale | Common Stock | 553,219 | $44.75 | $24.76M | |
| Avalon Ventures XI, L.P. | Option exercise | Stock Option (right to buy) | 4,968 | $0.00 | - | |
| Avalon Ventures XI, L.P. | Option exercise | Stock Option (right to buy) | 2,070 | $0.00 | - | |
| Avalon Ventures XI, L.P. | Option exercise | Stock Option (right to buy) | 2,070 | $0.00 | - | |
| Avalon Ventures XI, L.P. | Option exercise | Stock Option (right to buy) | 1,407 | $0.00 | - | |
| Avalon Ventures XI, L.P. | Option exercise | Stock Option (right to buy) | 836 | $0.00 | - | |
| Avalon Ventures XI, L.P. | Option exercise | Stock Option (right to buy) | 348 | $0.00 | - | |
| Avalon Ventures XI, L.P. | Option exercise | Stock Option (right to buy) | 348 | $0.00 | - | |
| Avalon Ventures XI, L.P. | Option exercise | Stock Option (right to buy) | 237 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
Janux Therapeutics, Inc. (JANX) had 10 insider filings in the last 90 days, with the most recent on 2026-08-01. The full record for JANX runs to 27 Form 4 filings, the earliest from 2024-10-18. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of JANX were filed in the last 90 days. 1 purchase is on record for this company.
1 insider sale of JANX was filed in the last 90 days, totaling $57K.
This page tracks JANX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add JANX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
